Addex Therapeutics Ltd

Equities

ADXN

CH0029850754

Biotechnology & Medical Research

Delayed Swiss Exchange 12:30:28 2024-03-28 pm EDT 5-day change 1st Jan Change
0.0956 CHF -1.65% Intraday chart for Addex Therapeutics Ltd +9.89% +107.83%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
ADRs Close Lower, Lixiang Education Holding Co. Ltd. Declines 19.6% DJ
Addex Therapeutics Plans Sale of American Depositary Shares MT
ADRs Close Lower; Jianpu Technology Declines 21% DJ
Top Premarket Decliners MT
ADRs End Higher; Argo Blockchain Climbs 22% DJ
ADRs Close Higher; Addex Therapeutics Climbs 21% DJ
ADRs End higher; Amarin Climbs 33% DJ
Transcript : Addex Therapeutics Ltd, Q3 2023 Earnings Call, Nov 29, 2023
Addex Therapeutics Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Addex Therapeutics' ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients CI
Addex Therapeutics Restores Compliance with Nasdaq's Minimum Bid Price Requirement MT
Addex Therapeutics to Effect ADS Ratio Change on Monday MT
Addex Therapeutics Gets Nasdaq Nod for New American Depositary Share Ratio MT
Addex Therapeutics to Amend American Depositary Shares Ratio MT
Addex Therapeutics to Undertake Reverse Split of American Depositary Shares MT
Addex-led Consortium Wins EUR4 Million Grant to Develop Mild Neurocognitive Disorders Drug MT
ADRs Slump; Fresh2 Group Ltd. Declines 16% DJ
Addex Therapeutics Ltd Announces ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Second Quarter 2024 CI
Addex Therapeutics Announces Data Published in Brain CI
Transcript : Addex Therapeutics Ltd, H1 2023 Earnings Call, Aug 10, 2023
Addex Therapeutics Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Addex Therapeutics Extends Partnership With Indivior on Substance Use Disorder Treatment Research MT
Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration CI
Addex Therapeutics Ltd announced that it has received CHF 2.7 million in funding from Indivior PLC CI
Addex Therapeutics Reports Positive Results in Study to Reduce Opioid Drug Addiction MT
Chart Addex Therapeutics Ltd
More charts
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company's clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson's disease and mGlu3 PAM for neurodegenerative disorders.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
0.0956 CHF
Average target price
0.16 CHF
Spread / Average Target
+67.36%
Consensus